Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Drug ID: DCL000357

Drug Information
SynonymsCID 10225366; SU-14813; 1H-Pyrrole-3-carboxamide, 5-((5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-N-((2S)-2-hydroxy-3-(4-morpholinyl)propyl)-2,4-dimethyl-; 627908-92-3; SU 14813; SU14813; CID10138259; 5-((5-Fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl)-N-(2-hydroxy-3-morpholin-4-ylpropyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide
IndicationMetastatic breast cancer
[ICD9: 174, 175   ICD10: C50]
Phase II    
Various CancersPhase I    

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
Canonical SMILESCC1=C(NC(=C1C(=O)NCC(CN2CCOCC2)O)C)C=C3C4=C(C=CC(=C4)F)NC3=O    
Isomeric SMILESCC1=C(NC(=C1C(=O)NC[C@@H](CN2CCOCC2)O)C)/C=C\3/C4=C(C=CC(=C4)F)NC3=O
Therapeutic ClassAntineoplastic Agents
CAS NumberCAS 627908-92-3
PubChem Compound IDCID 10138259.
PubChem Substance IDSID 15129502.
TargetVascular endothelial growth factor receptor 2Inhibitor[1][2][3]
Ref 1A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. To Reference
Ref 2Pfizer. Product Development Pipeline. March 31 2009. To Reference
Ref 3SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Mol Cancer Ther. 2006 Jul;5(7):1774-82. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links


Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543